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Although poliovirus receptor is required to mediate poliovirus infection, its role in mediating the tissue specificity of
poliovirus replication in natural infections remains unclear due to the presence of this receptor in nonsusceptible cells. It
has been hypothesized that CD44 has a role in determining the susceptibility of cells to poliovirus. To test this hypothesis,
we determined whether HepG2, a cultured cell line that lacks cell surface CD44, can support poliovirus replication. We
found that PV(1) Mahoney, PV(2)W2, and PV(3)Leon strains of poliovirus can replicate in HepG2 cells. Jurkat cells, which
also lack CD44, support PV replication. These results suggest that CD44 is not required for poliovirus replication in cultured
cells. To examine this question further, expression of CD44 in primary human monocytes was examined. Greater than 90%
of monocytes express the poliovirus receptor but only 6% of these cells are susceptible to poliovirus infection, making this
a good system to study blocks to poliovirus replication. 97% of primary human monocytes reacted with a monoclonal
antibody against CD44 that has been shown to block poliovirus binding and replication. This finding suggests that CD44 is
present on more cells that poliovirus infects, making CD44 unlikely to be the factor limiting poliovirus replication in human
tissues. q 1996 Academic Press, Inc.
Poliovirus (PV) replicates in a very limited number of Additionally, in several of the aforementioned studies,
blood cells were not removed from tissues that werecell types in a natural infection (1). These include a sub-
set of neurons in the central nervous system (CNS) and studied. However, despite the lack of knowledge of the
genuine distribution of cell-bound PVR, it seems likelyunidentified cells in the gastrointestinal mucosa. Other
primary primate cells do not replicate PV, although that cell surface PVR is present in sites that do not sup-
port PV replication. Since much data support the interpre-blocks to PV replication in primate cells are lost upon
culturing (2, 3). The poliovirus receptor (PVR), which is tation that PVR is the physiologically relevant receptor
required for PV infection, was identified by using a trans- mediating PV replication in a natural infection (10, 12),
fection assay for viral receptor function (4–6) and a the molecular mechanisms by which PV replication is
monoclonal antibody (mAb; D171) that blocks PV binding restricted in human tissues remain unknown.
to cells (7). Despite intensive work, an accurate and pre- Several viral receptors have been identified through
cise tissue-specific description of cell surface PVR in the use of anti-cell surface mAbs that specifically block
primary human tissues is not yet available (8). Initial stud- viral replication (13, 14). D171 and several cross-reacting
ies on the distribution of PVR in human tissues indicated mAbs are specific for the virus binding site in PVR (7,
ubiquitous expression of PVR mRNA and protein (5, 6, 9, 15, 16). Interestingly, an unrelated mAb, AF3, identified
10). An in situ nucleic acid hybridization study in (before the identification of PVR) for its ability to specifi-
transgenic animals revealed a more limited expression cally block PV (PV(1) and PV(2) only) replication in Hela
of PVR (3). Nonetheless, this study indicated expression cells (17) recognizes CD44 (18). There is not obvious
of PVR in several tissue types (thymus, lung, kidney) that immunological cross-reactivity between PVR and CD44
are thought not to be susceptible to PV. The human ge- (20; No. 944; M.F. and K.E., unpublished observations).
nome project describes PVR expression in bone, brain, CD44 alone does not function as a poliovirus receptor
endothelial cells, kidney, lung, and prostrate (11). The (18). The term ‘‘CD44’’ refers to a heterogeneous set of
latter two studies did not distinguish between the splice gene products derived from a single gene by alternative
variants of PVR, some of which encode secreted forms. splicing and differential glycosylation (19). A panoply of
functions has been ascribed to these molecules: unifying
these diverse functions is the ability of CD44 to bind1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (504) 568-2918. E-mail: mfreis@lsumc.edu. hyaluronic acid.
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The purpose of the current work is to study the role replication was blocked by D171 (anti-PVR; Table 1). The
replication was not blocked by IM7 (Table 1), an anti-of CD44 in PV replication. The finding that mAbs against
CD44 block PV binding to cells and that PVR may be CD44 mAb that was shown to block PV (18). In addition,
AF3 (kindly provided by M. Shepley) did not block PV(1)expressed in tissues that do not support PV replication,
led to a model that a physical complex between PVR and replication in HepG2 cells while it reduced PV(1) replica-
tion in Hela cells 60% (data not shown). Visually, it ap-CD44 exists (18). The presence of a putative complex
between PVR and CD44 could limit PV replication to a peared that all the HepG2 cells became infected and
lysed. In other experiments, Jurkat clone E6 cells (ATCC)subset of the cells that express both CD44 and PVR
and thus confer the tissue specificity required for PV were demonstrated to express PVR, but not CD44 ((22);
data not shown). These cells also supported high levelsreplication in a natural infection (18). In this case, this
complex, rather than PVR alone, would be required for of PV(1) replication (data not shown).
There may be strain-specific differences in the impor-the entry of PV into susceptible tissues. Predictions of
this model are that CD44 may be required for or may tance of CD44 in PV replication. AF3 has differential abil-
ity to block the three strains of PV: it has the highestenhance PV replication. Furthermore, one would expect
the distribution of CD44 in human tissues to correspond blocking ability against PV(2)W-2 and lowest against
PV(3) (17, 18). This suggests that if CD44 has a role into sites of PV replication. In this work we tested whether
cells lacking CD44 support PV replication and whether PV replication, it may have a more important role for PV(2)
and it may have a different role for PV(3). A predictionthe distribution of CD44 in human tissues corresponds
to PV susceptibility. of this is that PV(2) may not replicate in HepG2 cells.
Therefore, PV(2)W-2 and PV(3) Leon were tested for theirAlthough many cultured cells express CD44, the hu-
man hepatocellular carcinoma cell line, HepG2, is re- ability to replicate in HepG2 cells. We found that PV(2)W-
2 and PV(3) Leon replicate in HepG2 cells to similarported to not express it. Of the cultured human cell lines
analyzed by the Fifth International Workshop on Human extents as in Hela cells (Fig. 2). These results show that
CD44 is not required for replication of the three serotypesLeukocyte Antigens, HepG2 was the only monolayer cell
line not expressing CD44 (20). We tested whether these of PV in cultured cells.
It is possible that CD44 is present in HepG2 cells, butcells express PVR and CD44. Positive control staining of
Hela cells (Fig. 1) revealed staining of both cell surface that we did not detect it because its form on these cells
lacks the epitope recognized by the three mAbs that weproteins. As expected, HepG2 cells express PVR, but
not CD44 (Fig. 1). The apparent difference in PVR levels used. However, we think this is unlikely because the
CD44 reference mAb, A3D8, for the Fifth Internationalbetween Hela cells and HepG2 cells may be due to the
different fluorochrome used: for unknown reasons, goat Workshop on Human Leukocyte Differentiation Antigens,
was reported to not react with HepG2 cells (20). IM7 andanti-mouse PE usually yields higher levels of fluores-
cence than goat anti-mouse FITC with D171. In this ex- A3D8 compete with AF3 (18). Furthermore, A3D8 reacts
with an epitope encoded by exons 1–5 in the CD44 geneperiment, the choice of fluorochrome is not relevant to
the study. Relative levels of cell surface expression be- (23) and, although extensive alternative splicing of CD44
occurs, no splice variants lacking these exons have beentween different cell lines cannot be accurately deter-
mined in these experiments that compare relative fluo- reported (19). It is interesting that the efficiency of replica-
tion for PV(2)W-2 and PV(3) did not seem to vary signifi-rescence levels with an isotype-matched negative con-
trol for each cell line. Similar results were obtained using cantly based on the presence or absence of CD44 (Fig.
2), since there is a significant difference in the extent ofthree different anti-CD44 mAbs (G44-26 and IM7; Phar-
mingen; AF3 (kindly supplied by M. Shepley)). CD44 inhibition by AF3 between the two serotypes (17). Our
results suggest that CD44 is not required for PV replica-binds hyaluronic acid, so hyaluronic acid conjugated to
fluorescein (HA-FI) (21) can be used to confirm the pres- tion in cultured cells. It is possible that our finding is
relevant only in cultured cells and that primary humanence of CD44 (22). Hela cells, but not HepG2 cells, bound
HA-FI (Fig. 1D). Although some cells express CD44, but tissues require CD44 to support PV replication. Resolu-
tion of this question will await the detection of a primaryfail to bind HA (19, 22), in this case, we found a correlation
between the presence of CD44 and HA binding. The human tissue expressing PVR but lacking CD44. This
question may be addressed in CD44-knockout/PVR-posi-heterogeneity of HA binding to Hela cells is very likely a
reflection of the regulation of CD44 binding of HA. In tive mice, if they can be generated. Mouse Ltk-cells,
which were used to generate mouse transfectants ex-other experiments, 100% of Hela cells bound HA-FI (not
shown). pressing PVR (4, 5) react with IM7, so they express
mouse CD44 (K.E. and M.F., unpublished observations).Next we determined whether the CD44-negative cells
were susceptible to PV. HepG2 cells were infected with PVR is expressed on the cell surface of 90% of pri-
mary human monocytes, as demonstrated by specificPV(1) Mahoney at an m.o.i. of 10, samples withdrawn
and virus titrated in separate plaque assays on Hela immunological staining and flow cytometric analysis (24).
The presence of PVR on blood cells may explain thecells. HepG2 cells supported PV(1) replication and this
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FIG. 1. HepG2 cells express PVR, but not AF3CD44H/Hermes-2. Hela cells (obtained from E. Wimmer; upper row) or HepG2 cells (obtained from
J. Finley of the Core Cell Culture Facility of the LSUMC Neuroscience Center of Excellence and Department of Biochemistry and Molecular Biology;
lower row) were scraped from monolayer cultures and stained as described (24, 32) with a negative isotype-matched control, anti-PVR, (D171 (7)
purified by binding to a protein A–Sepharose column) or anti-AF3CD44H/Hermes-2 (IM7 [Pharmingen] for HepG2 cells or G44-26 [Pharmingen] for
Hela cells) followed by goat anti-mouse conjugated to a fluorochrome (FITC in each case except PVR in HeLa cells, which was visualized with
goat anti-mouse PE). In these one-color analyses, relative fluorescence (X-axis) is plotted against cell number (Y-axis). The horizontal bars indicate
the levels above background staining that a signal is considered positive, relative to the isotype-matched control. A shift of a peak rightward
indicates positive staining. In the fourth set of diagrams, the cells were stained with hyaluronic acid conjugated to fluorescein (HA-FI). HA-FI was
synthesized following the protocol of DeBelder (1975). To demonstrate specificity of HA-FI binding, the HA-FI signal in Hela cells was completely
competed away with unlabeled hyaluronic acid (M.F. and K.E., unpublished observations).
apparent ubiquity of PVR. There are a number of studies correlates with strain-specific neurovirulence (28). How-
ever, although 90% of primary human monocytes ex-suggesting that PV replication in hematopoietic cells may
occur in natural infections (25, 26). PVR-positive, primary press cell surface PVR, only 6% of monocytes support
PV replication (27), suggesting that there are blocks tohuman monocytes support PV replication within 24 hr of
extravasation, suggesting that the cells were susceptible PV replication in primary human monocytes. These un-
identified blocks may be similar to blocks to PV replica-in the body and, further, that monocytes (or macro-
phages) may be infected during a natural PV infection (24, tion present in other PV-resistant, PVR-expressing human
tissues. Primary human monocytes are easy to obtain27). Other work has shown that replication in monocytes
and work with. For these reasons, PV replication in pri-
mary human monocytes may be an excellent model sys-TABLE 1
tem to study molecular determinants of PV tissue tro-
HepG2 Cells Support PV(1)Mahoney Replicationa pism.
The epitope recognized by AF3 has been termedAntibody Viral titer- T0 Viral titer- T23
‘‘AF3CD44H’’ (18), denoting that it may be specific for an
Mouse IgG1 control 7.5 1 104 2.8 1 108 epitope on a subset of CD44H molecules. This is be-
Anti-PVR (D171, mouse IgG1) 8.5 1 104 5.0 1 105 cause AF3 recognizes a 100-kDa antigen from Hela cells,
Rat IgG2b control 9.5 1 103 3.4 1 106 brain tissue, and human chromosome 19 somatic cell
Anti-CD44 (IM7, Rat IgG2b) 1.8 1 104 3.2 1 107
hybrids (17), while mAbs against Hermes-2 recognize
multiple species. The Fifth International Workshop ona Specific antibody or appropriate negative control (isotype-matched),
diluted into 0.5 ml of RPMI / 5% fetal calf serum, was added to mono- Human Differentiation Antigens recognized three epi-
layers of HepG2 cells. After 1 hr incubation at room temperature with topes common to the various forms of CD44: epitope 1
gentle rocking, PV(1) Mahoney (obtained from E. Wimmer) was added (Hermes-2), epitope 2 (Hermes-1), and epitope 3
at an m.o.i. of 10 and allowed to adsorb for another 30 min at room
(Hermes-3) (29, 30). Two independently derived and well-temperature. Media were added, samples withdrawn at the indicated
characterized mAbs against CD44/Hermes-2 mAbstimepoints (in hours), and virus yield (expressed in PFU/ml culture
supernatant) was determined in a separate plaque assay in Hela cells. (A3D8 and IM7) block PV binding to cells to similar ex-
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FIG. 2. HepG2 cells support PV(2)W2 and PV(3) Leon replication. Hela cells (solid lines) or HepG2 cells (dotted lines) were infected with PV(2)W2
(squares) or PV(3)Leon (circles) at an m.o.i. of 10. Both viruses were obtained from the ATCC. Samples were withdrawn at the indicated timepoints
and titrated on a separate plaque assay using Hela cells.
tents as AF3 and compete with radiolabeled AF3 to the visualize distinct cell surface markers on individual cells.
Dual-staining experiments (PVR and CD14, PVR andsame extent as unlabeled AF3 (18). This suggests that
the AF3CD44H epitope is very close to or identical with CD44, CD44 and CD14) for these three markers con-
firmed that the same cells express all three cell surfaceepitope 1 of CD44 (Hermes-2) (29, 30). The different reac-
tivity may be due to differential affinity of the mAbs or proteins (data not shown). Therefore, the majority of pri-
mary human monocytes express the AF3CD44H/Hermes-differential expression of the antigens in the cells tested.
In the current work, AF3, IM7, and an anti-CD44 Hermes- 2 epitope. This finding of the AF3CD44H/Hermes-2 antigen
on greater than 85% of primary human monocytes sug-2 mAb that cross-reacts with IM7, (G44-26) were used
to study this epitope in monocytes. Since the precise gests that the distribution of the AF3CD44H/Hermes-2
does not mediate the restriction of PV replication to 6%relationship between the AF3CD44H and Hermes-2 epi-
topes is not clear, yet both classes of mAbs inhibit PV of these cells. This suggests that the restriction of PV
replication in primary human monocytes is not mediatedbinding to cells (18), in the current report, the epitope
will be referred to as AF3CD44H/Hermes-2. by the presence of AF3CD44H/Hermes-2. Thus, CD44 is
similar to PVR in the sense that the number of cells thatTo determine whether AF3CD44H/Hermes-2 has a role
in the restriction of PV replication, we stained primary express the cell surface protein exceeds the number
of cells that are susceptible to PV infection. Since PVhuman monocytes for AF3CD44H/Hermes-2 and PVR. If
a complex between PVR and CD44 is required for PV replication in primary human monocytes is a primary hu-
man cell model system for studying blocks to PV replica-replication in human tissues, then AF3CD44H/Hermes-2
should be expressed only in the subset of monocytes tion, this may suggest that the presence of PVR and CD44
does not determine PV tissue tropism in human tissues.(6%) that are susceptible to PV. As shown previously (24),
the majority of primary human monocytes express PVR In other experiments, two anti-AF3CD44H/Hermes-2
mAbs IM7 and G44-26 showed little to no inhibition ofand CD14, the LPS-binding protein receptor (a monocyte
marker within PBMCs; Fig. 3). IM7, a rat anti-mouse CD44 PV replication in monocytes while D171 (anti-PVR) fully
inhibited PV(1) replication in monocytes (data not shown).mAb, cross-reacts with human CD44 and blocks PV bind-
ing to cells (18). Although CD44 is known primarily as a The reason for the difference between our findings and
others’ may be that our assay is different from the pub-lymphocyte marker, we found that 97.0 { 1.2% of mono-
cytes react with IM7 (Fig. 3). Of monocytes, 86.9 { 7.8% lished assays (17, 18). The original observation was that
AF3 inhibited replication in Hela cells; later work showedreacted with G44-26, an anti-human Hermes-2-CD44. Of
monocytes, 97.7% reacted with AF3 (kindly provided by inhibition of binding of radiolabeled PV(2)W-2 to Hela
cells. However, even if mAbs against the AF3CD44H/M. Shepley; data not shown). The use of different fluoro-
chromes in dual staining experiments permits one to Hermes-2 antigen were shown to inhibit PV(2)W2 binding
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FIG. 3. The majority of primary human monocytes express AF3CD44H/Hermes-2. Ficoll (Pharmacia)-purified primary blood mononuclear cells
(obtained under an LSUMC IRB approved protocol) were immunostained and analyzed by flow cytometric analysis. Data shown in this figure are
from the monocyte gate (by size and shape). The top three panels show the level of staining that was obtained with isotype-matched negative
controls for each mAb (shown directly below) used: these nonspecific levels of staining were used to set the levels above which staining was
considered positive, as indicated by the horizontal bar. In these one-color analyses, relative fluorescence (X-axis) is plotted against cell number
(Y-axis). The lower panels show staining for PVR (D171, mouse IgG1; 61.5% positive), CD14 (Becton-Dickinson, mouse IgG2b; 72.9% positive), and
CD44 levels (IM7, rat IgG2b; 96.4% positive). In five independent stainings of primary human monocytes, an average of 97.0% { 1.2% were positive
for IM7 reactivity and 86.9 { 7.8% were positive for G44-26 (not shown).
to primary human monocytes, such a finding would not has no role in PV replication. In this case, the ability of
anti-CD44 mAbs to block PV binding may be secondaryreveal whether CD44 is required for PV replication in
primary human monocytes. Our finding that there is a to a normal interaction between PVR and CD44. If this
is true, then the observation that anti-AF3CD44H/Hermes-significant discrepancy between the expression of the
AF3CD44H/Hermes-2 epitope and PV replication in pri- 2 mAbs inhibit PV binding to cells may be due to the
mAbs incidentally overlapping the poliovirus binding sitemary human monocytes strongly suggests that other fac-
tors mediate the specific replication of PV. on PVR.
Four possible roles for CD44 in PV replication remain.
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